Skip to main content
Clinical Trials/EUCTR2016-002163-34-DE
EUCTR2016-002163-34-DE
Active, not recruiting
Phase 1

Comparative Effectiveness Trial of Transoral Head and Neck Surgery followed by adjuvant Radio(chemo)therapy versus primary Radiochemotherapy for Oropharyngeal Cancer (TopROC)

niversity Medical Center Hamburg-Eppendorf0 sites280 target enrollmentJune 14, 2017

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
niversity Medical Center Hamburg-Eppendorf
Enrollment
280
Status
Active, not recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 14, 2017
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
niversity Medical Center Hamburg-Eppendorf

Eligibility Criteria

Inclusion Criteria

  • Histologically proven SCC of the oropharynx; T1, N2a\-c, M0; T2, N1\-2c, M0; T3, N0\-2c, M0, with only amendable to transoral resection)
  • Primary tumor must be resectable through transoral approach
  • p16 immunohistochemitry by local pathology or FFPE tissue must be available for central HPV diagnostic
  • Written and signed informed consent
  • Briefing through surgeon and radiation oncologist
  • ECOG PS \=2, Karnofsky PS \= 60 %
  • Curative treatment intent
  • Adequate bone marrow function: leucocytes \> 3\.0 x 109/L, neutrophils \> 1\.5 x 109/L, platelets \> 80 x 109/L, hemoglobin \> 9\.5 g/dL
  • Adequate liver function: Bilirubin \< 2\.0 g/dL, SGOT, SGPT, \< 3 x ULN
  • If of childbearing potential, willingness to use effective contraceptive method for the study duration and 2 months post\-dosing.

Exclusion Criteria

  • Prior invasive malignancy except controlled skin cancer or carcinoma in situ of cervix
  • Unknown primary (CUP), nasopharynx, hypopharynx, laryngeal or salivary gland cancer
  • Metastatic disease
  • Serious co\-morbidity, e.g. high\-grade carotid artery stenosis, congestive heart failure NYHA grade 3 and 4, liver cirrhosis CHILD C
  • Hemoglobin level \<9\.5g/dl within 4 weeks before randomization
  • Pregnancy or lactation
  • Women of child\-bearing potential with unclear contraception
  • Previous treatment with chemotherapy, radiotherapy, EGFR\-targeting agents or surgery exceeding biopsy in head and neck
  • Concurrent treatment with other experimental drugs or participation in another clinical trial with any investigational drug within 30 days prior to study screening
  • Social situations that limit compliance with study requirements or patients with an unstable condition (e.g., psychiatric disorder, a recent history of drug or alcohol abuse, interfering with study compliance, within 6 months prior to screening) or otherwise thought to be unreliable or incapable of complying with the requirements of the protocol

Outcomes

Primary Outcomes

Not specified

Similar Trials